Yüklüyor......
Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline
AIMS/INTRODUCTION: Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of drugs for the treatment of type 2 diabetes mellitus that improve control of plasma glucose and bodyweight, giving great hope for the clinical utility of these agents. However, it is unclear for which patients SGL...
Kaydedildi:
| Yayımlandı: | J Diabetes Investig |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6031493/ https://ncbi.nlm.nih.gov/pubmed/29032638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.12761 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|